

Christopher D Breder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306382/publications.pdf>

Version: 2024-02-01

10
papers

63
citations

1936888
4
h-index

1588620
8
g-index

10
all docs

10
docs citations

10
times ranked

81
citing authors

#	ARTICLE	IF	CITATIONS
1	Whatâ€™s the Regulatory Value of a Target Product Profile?. Trends in Biotechnology, 2017, 35, 576-579.	4.9	19
2	Exposureâ€™ and Doseâ€™response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics, 2018, 40, 95-102.e2.	1.1	14
3	Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications. PLoS ONE, 2017, 12, e0178104.	1.1	11
4	A Critical Evaluation of Safety Signal Analysis Using Algorithmic Standardised MedDRA Queries. Drug Safety, 2018, 41, 1375-1385.	1.4	8
5	Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. Therapeutic Innovation and Regulatory Science, 2019, 53, 752-758.	0.8	5
6	Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications. Pharmacological Research, 2019, 139, 166-172.	3.1	3
7	A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries. Pharmaceutical Medicine, 2016, 30, 103-108.	1.0	2
8	Investigation of Factors Associated With Immunogenicity Labeling Updates and Characteristics of Biologics License Applications. Clinical Pharmacology and Therapeutics, 2021, 110, 1381-1388.	2.3	1
9	Correlates of time to approval and other clinical development periods. Drug Discovery Today, 2019, 24, 1871-1876.	3.2	0
10	A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role. Therapeutic Innovation and Regulatory Science, 2021, 55, 262-269.	0.8	0